vs
Side-by-side financial comparison of ACHIEVE LIFE SCIENCES, INC. (ACHV) and Alpha Teknova, Inc. (TKNO). Click either name above to swap in a different company.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Alpha Teknova, Inc. is a life sciences company that develops and manufactures specialized reagents, cell culture media, and custom laboratory solutions. It serves biopharmaceutical, molecular diagnostic, and academic research clients, primarily operating across the North American market to support drug discovery, diagnostic testing, and life science research workflows.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $10.0M | ||
| Q3 25 | — | $10.5M | ||
| Q2 25 | — | $10.3M | ||
| Q1 25 | — | $9.8M | ||
| Q4 24 | — | $9.3M | ||
| Q3 24 | — | $9.6M | ||
| Q2 24 | — | $9.6M | ||
| Q1 24 | — | $9.3M |
| Q4 25 | — | $-4.8M | ||
| Q3 25 | — | $-4.3M | ||
| Q2 25 | — | $-3.6M | ||
| Q1 25 | — | $-4.6M | ||
| Q4 24 | — | $-5.7M | ||
| Q3 24 | — | $-7.6M | ||
| Q2 24 | — | $-5.4M | ||
| Q1 24 | — | $-8.1M |
| Q4 25 | — | 32.5% | ||
| Q3 25 | — | 30.7% | ||
| Q2 25 | — | 38.7% | ||
| Q1 25 | — | 30.7% | ||
| Q4 24 | — | 23.0% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 29.2% | ||
| Q1 24 | — | 23.8% |
| Q4 25 | — | -46.2% | ||
| Q3 25 | — | -38.4% | ||
| Q2 25 | — | -32.9% | ||
| Q1 25 | — | -50.7% | ||
| Q4 24 | — | -60.7% | ||
| Q3 24 | — | -77.6% | ||
| Q2 24 | — | -53.0% | ||
| Q1 24 | — | -86.0% |
| Q4 25 | — | -47.7% | ||
| Q3 25 | — | -41.0% | ||
| Q2 25 | — | -34.7% | ||
| Q1 25 | — | -47.4% | ||
| Q4 24 | — | -61.7% | ||
| Q3 24 | — | -79.0% | ||
| Q2 24 | — | -55.8% | ||
| Q1 24 | — | -87.2% |
| Q4 25 | — | $-0.08 | ||
| Q3 25 | — | $-0.08 | ||
| Q2 25 | — | $-0.07 | ||
| Q1 25 | — | $-0.09 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | — | $-0.13 | ||
| Q1 24 | — | $-0.20 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
